Compounds for the treatment of BRAF-associated diseases and disorders
AssigneePfizer Inc.
InventorsPatrick Michael Doerner Barbour, Tanna Marie Bettendorf, Dean Russell Kahn, Alex Andrew Kellum, Ellen Ruth Laird, David Austin Moreno, Li Ren
Life of this patent
Estimating the term…
Abstract
Provided herein is a compound of the Formula I: or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R4, R5, R6, R7 and L are as defined herein, for the treatment of BRAF-associated diseases and disorders, including BRAF-associated tumors.
Claims16
A compound which is N-(2-chloro-3-((5-chloro-3-methyl-4-oxo-3,4-dihydroquinazolin-6-yl)amino)-4-fluorophenyl)-3-fluoroazetidine-1-sulfonamide having the structure:
A pharmaceutically acceptable salt of the compound N-(2-chloro-3-((5-chloro-3-methyl-4-oxo-3,4-dihydroquinazolin-6-yl)amino)-4-fluorophenyl)-3-fluoroazetidine-1-sulfonamide, which has the structure:
A compound which is N-(2-chloro-3-((5-chloro-3-methyl-4-oxo-3,4-dihydroquinazolin-6-yl)amino)-4-fluorophenyl)-3-fluoroazetidine-1-sulfonamide having the structure:
- or a pharmaceutically acceptable salt thereof.
A method of treating a BRAF-associated tumor in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of N-(2-chloro-3-((5-chloro-3-methyl-4-oxo-3,4-dihydroquinazolin-6-yl)amino)-4-fluorophenyl)-3-fluoroazetidine-1-sulfonamide or a pharmaceutically acceptable salt thereof, wherein said BRAF-associated tumor is a cancer selected from lung cancer, melanoma, colorectal cancer, breast cancer, pancreatic cancer, thyroid cancer, prostate cancer, adenoid cystic carcinoma, appendiceal cancer, small intestine cancer, head and neck squamous cell carcinoma, angiosarcoma, bladder carcinoma, plasma cell neoplasm, hepato-pancreato-biliary carcinoma, ovarian carcinoma, renal cell carcinoma, neuroendocrine cancer, cholangiocarcinoma and CNS cancers, wherein said BRAF-associated tumor has a BRAF Class II mutation.
Dependencies are inferred from the claim text.